Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Cardiff, United Kingdom, focused on developing therapeutics for oncology, immunology, and metabolic diseases. The company's lead candidate, Tolimidone, is a selective lyn kinase activator currently in Phase II trials for Type 1 diabetes treatment. A second clinical-stage asset, MTX110, is in Phase I development for pediatric brain tumors, including diffuse intrinsic pontine glioma, diffuse midline glioma, and medulloblastoma. The company maintains a pipeline addressing familial adenomatous polyposis and non-muscle invasive bladder cancer.

Biodexa operates three proprietary drug delivery platforms. Q-Sphera is a polymer microsphere technology designed for sustained-release formulations. MidaSolve is an oligosaccharide nanotechnology that enables localized liquid delivery of poorly soluble drugs directly into tumors. MidaCore comprises gold nanoparticles intended to facilitate targeted delivery of chemotherapeutic and immunotherapeutic agents. The company has established collaboration agreements with Janssen and Melior Therapeutics.

The company operates with a lean structure of 13 full-time employees and is listed on Nasdaq. Biodexa was incorporated in the United Kingdom and was previously known as Midatech Pharma plc before rebranding in March 2023. The company was founded in 2000.